<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077415</url>
  </required_header>
  <id_info>
    <org_study_id>CTRG-LUN012</org_study_id>
    <secondary_id>CDR0000350313</secondary_id>
    <secondary_id>NCI-6256</secondary_id>
    <nct_id>NCT00077415</nct_id>
  </id_info>
  <brief_title>3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized Phase II Study Of Triapine® Alone Versus Triapine and Gemcitabine As Second-Line Treatment Of Advanced Non-Small-Cell-Lung Cancer In Patients Who Had Prior Gemcitabine With Evaluation Of The Effect Of Triapine® On Gemcitabine Pharmacokinetics and Cellular Uptake In Peripheral Mononuclear Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Therapeutics Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as 3-AP and gemcitabine, work in different ways&#xD;
      to stop tumor cells from dividing so they stop growing or die. Giving more than one drug may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving 3-AP together with gemcitabine as&#xD;
      second-line therapy works in treating patients with recurrent stage III or stage IV non-small&#xD;
      cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the objective response rate in patients with stage III or IV recurrent&#xD;
           non-small cell lung cancer treated with 3-AP (Triapine®) and gemcitabine as second-line&#xD;
           therapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response duration, median time to progression, and overall survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the effect of 3-AP (Triapine®) on gemcitabine pharmacokinetics and cellular&#xD;
           uptake into peripheral mononuclear cells in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study. Patients are stratified according to&#xD;
      participating center.&#xD;
&#xD;
      Patients receive 3-AP (Triapine®) IV over 4 hours and gemcitabine IV over 30 minutes on days&#xD;
      1, 8, and 15*. Treatment repeats every 28 days for up to 6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      NOTE: *For course 1 only, gemcitabine is administered alone on day 1 and in combination with&#xD;
      3-AP (Triapine®) on days 8 and 15.&#xD;
&#xD;
      Patients are followed every 3 months for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 15-31 patients will be accrued for this study within 7.5-21&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response as assessed by RECIST criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by NCI CTCAE v3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">31</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed* non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage III or IV disease&#xD;
&#xD;
               -  One of the following cellular types:&#xD;
&#xD;
                    -  Adenocarcinoma&#xD;
&#xD;
                    -  Non-diffuse bronchoalveolar cell carcinoma&#xD;
&#xD;
                    -  Large cell carcinoma&#xD;
&#xD;
                    -  Squamous cell carcinoma NOTE: *A repeat biopsy of any accessible tumor site&#xD;
                       is required if &gt; 5 years have elapsed since the initial diagnosis&#xD;
&#xD;
          -  Progressive disease after 1 prior gemcitabine-containing chemotherapy regimen for&#xD;
             stage III or IV NSCLC and must have achieved, at least once, a partial response,&#xD;
             complete response, or stable disease during therapy&#xD;
&#xD;
               -  Not a primary non-responder and experienced only progressive disease during&#xD;
                  gemcitabine-containing chemotherapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2 OR&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  No glucose-6-phosphate dehydrogenase (G6PD) deficiency&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT ≤ 2.5 times ULN (5 times ULN if liver metastases are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No prior uncontrolled cardiac disease&#xD;
&#xD;
          -  No myocardial infarction within the past 12 months&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No coronary artery disease&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No uncontrolled symptomatic pulmonary disease&#xD;
&#xD;
          -  No pulmonary disease that requires oxygen therapy&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy within the past 5 years except completely treated carcinoma in&#xD;
             situ of the cervix or nonmelanoma skin cancer&#xD;
&#xD;
          -  No prior allergic reaction attributed to compounds of similar chemical or biological&#xD;
             composition to study agents&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brigette Ma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Prince of Wales Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sydney Cancer Centre at Royal Prince Alfred Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital - Perth</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei Cancer Center at Yonsei University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute at National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National University of Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>119260</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Singapore International Medical Centre</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
  </location_countries>
  <verification_date>August 2006</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2004</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>adenocarcinoma of the lung</keyword>
  <keyword>bronchoalveolar cell lung cancer</keyword>
  <keyword>large cell lung cancer</keyword>
  <keyword>squamous cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

